Your detected browser is unsupported. Please update your browser for the best biopatch.com experience.
Protect All Lines. Protect All Lives.™
Peripheral intravenous (PIV) catheters are the most frequently used invasive device in healthcare.5
- Approximately 330 million PIV catheters are sold each year in the United States and an estimated 70% of acute care patients need a short PIV catheter.5,6
- Researchers have reported the risks of catheter-related BSI that are related to PIV catheters are under-evaluated.5
- Researchers have identified a significant potential for infections in large numbers of patients based on volume of PIV catheter use.7
- New data collection methods introduced by the NHSN now allow for reporting of non-central line associated, laboratory confirmed BSIs.8
- The 2011 CDC Guidelines state: There is no need to replace peripheral catheters more frequently than every 72-96 hours to reduce risk of infection and phlebitis in adults [Category1B]
- The 2011 Infusion Nurses Society Standards of Practice state: The nurse should consider replacement of the short peripheral catheter when clinically indicated...the decision to replace the short peripheral catheter should be based on assessment of the patient's condition; access site; skin and vein integrity; length and type of prescribed therapy; venue of care; integrity and patency of VAD; dressing; and stabilization device.
- 60% of CRBSI originate from the patient’s own skin.2
- Regardless of how a BSI occurs (via central line in the bloodstream or PIV catheters in the bloodstream), the end result is still a BSI.
BIOPATCH® is the ONLY IV dressing with CHG PROVEN in multiple Randomized Control Trials to reduce the incidence of CRBSIs.9
For a comprehensive summary, please review the PIV Executive Monograph.